# Teleflex Incorporated (TFX)

> Source: Nexqual · https://nexqual.com/TFX · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Teleflex Incorporated (TFX), nexqual.com/TFX" · informational, not investment advice.

**Price:** USD 136.58 (+4.74% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 130.4 · day 131.49–137.02 · 52w 100.18–145 · market cap $5.79B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $2.25B, net income -$1.03B (-45.8% margin), free cash flow $168M (SEC filings).
- 3 of 80 tracked superinvestors hold TFX (13F, Q2 2026): 0 new, 0 added, 3 reduced, 0 unchanged.
- Analysts: Buy (mean 2.17 on a 1–5 scale) (12 analysts), mean target USD 154 (range 138–170).
- Total return with dividends: 1Y +4.3% vs S&P 500 +14.9%; 5Y -62.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.89, revenue estimate $565M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.81B | $2.79B | $1.71B | $1.70B | $1.99B | $2.25B |
| Gross profit | $1.55B | $1.53B | $1.04B | $1.04B | $1.12B | — |
| Operating income | $628M | $500M | $259M | $104M | $118M | $44.4M |
| Net income | $485M | $363M | $356M | $69.7M | -$906M | -$1.03B |
| EPS (diluted) | $10.23 | $7.68 | $7.53 | $1.48 | -$20.25 | — |
| Free cash flow | $581M | $264M | $160M | $211M | $1.4M | $168M |
| Gross margin | 55.2% | 54.9% | 60.7% | 61.0% | 56.2% | — |
| Operating margin | 22.4% | 17.9% | 15.1% | 6.1% | 5.9% | 2.0% |
| Net margin | 17.3% | 13.0% | 20.8% | 4.1% | -45.4% | -45.8% |
| Revenue growth | +10.7% | -0.7% | -38.6% | -0.8% | +17.2% | — |
| Cash + short-term investments | $445M | $292M | $223M | $248M | $379M | — |
| Total debt | $1.85B | $1.71B | $1.82B | $1.66B | $2.64B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 2.6x · EV/EBITDA 43.0x · EV/Sales 3.7x · P/FCF 34.4x · P/B 2.0x · FCF yield 2.91% · Earnings yield -17.83% · Dividend yield (paid, TTM) 1.03% · Buyback yield (TTM) 4.32% · Net debt $2.51B · EV $8.30B
P/E at fiscal year-ends: Dec 2024 120.3x, Dec 2023 33.1x.

## Superinvestors (SEC 13F-HR, Q2 2026)
3 of 80 tracked investors hold TFX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Abrams Bison Investments, LLC |  | 4.91% | $101M | Reduced -20.7% |
| Seth Klarman | Baupost Group | 3.30% | $179M | Reduced -11.7% |
| Richard Pzena | Pzena Investment Management | 0.22% | $76.5M | Reduced -13.7% |

## Analysts
Consensus Buy (mean 2.17 on a 1–5 scale), 12 analysts; mean target USD 154 (low 138, high 170).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Truist Securities | Target lowered | Hold | $150 → $142 |
| 2026-09-28 | B of A Securities | Upgrade | Neutral → Buy | $145 → $158 |
| 2026-08-25 | Needham | Target raised | Buy | $159 → $170 |
| 2026-08-11 | UBS | Target raised | Neutral | $145 → $158 |
| 2026-08-10 | Truist Securities | Target raised | Hold | $143 → $150 |
| 2026-08-07 | Piper Sandler | Target raised | Overweight | $160 → $169 |
| 2026-07-31 | Needham | Target raised | Buy | $147 → $159 |
| 2026-07-28 | UBS | Initiated | Neutral | $145 |
| 2026-07-15 | Mizuho | Target raised | Neutral | $140 → $145 |
| 2026-07-09 | BMO Capital | Initiated | Outperform | $159 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +4.3% | -62.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +4.4% | -17.7% |
| Volatility (annualized) | 40.0% | 34.5% |
| Max drawdown | -24.1% (Oct 2025→Jan 2026) | -71.8% (Oct 2021→Jan 2026) |

## Peers (Medical Instruments & Supplies)
MMSI (Merit Medical Systems, Inc.) USD 93.94 +2.78% · STVN (Stevanato Group S.p.A.) USD 19.5 +3.61% · MMED (MiniMed Group, Inc.) USD 18.29 +2.75% · BLCO (Bausch + Lomb Corporation) USD 17.43 +1.46% · ICUI (ICU Medical, Inc.) USD 168.33 +4.66% · ATR (AptarGroup, Inc.) USD 128.1 +1.97%

## More
Full page: https://nexqual.com/TFX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Americas | $348.8M | 61.2% | +14.4% |
| EMEA | $145.5M | 25.5% | +62.0% |
| Asia | $76.0M | 13.3% | +59.5% |
| Total revenue | $570.3M | 100% | — |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Vascular | $246.3M | 43.2% | +9.0% |
| Interventional | $211.9M | 37.1% | +86.1% |
| Surgical | $112.1M | 19.7% | +9.1% |
| Total revenue | $570.3M | 100% | — |

## Revenue by region (fiscal year ended 2025-12-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $1.18B | 59.3% | +9.5% |
| Europe | $484.7M | 24.3% | +39.3% |
| Asia & Asia Pacific | $218.0M | 10.9% | +21.4% |
| All Other | $108.1M | 5.4% | +16.6% |
| Total revenue | $1.99B | 100% | — |

## Customer concentration

Period ended 2025-09-28: 88%, 2% of revenue from unnamed direct customers (10-Q, filed 2025-11-06).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.89 | $1.82 | +3.7% | $565.4M | 11 |
| Next quarter (ends 2026-12-31) | $2.12 | $2.23 | -4.8% | $584.0M | 11 |
| Current fiscal year (ends 2026-12-31) | $7.08 | $6.70 | +5.7% | $2.27B | 10 |
| Next fiscal year (ends 2027-12-31) | $10.94 | $10.58 | +3.4% | $2.37B | 12 |